Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!
EULAR 2022 Conference
- Home
- EULAR Conference 2022
Novel biomarkers: Rheumatic & Musculoskeletal Diseases
Biomarker studies have added value to real-world data collections in inflammatory arthritis, and some of them have the potential to be used in routine clinical practice.
Our Recent Articles
Types / Technology
Indications
Title
Musculoskeletal Imaging in Rheumatology
Summary
There are about 200 different types of rheumatic and musculoskeletal diseases (RMDs) that affect both children as well as adults. The group of diseases is usually caused owing to a compromised immune system or by inflammation, infections, and gradual deterioration caused in the joints, muscles, and bones.
Article Type
Research And Development
Title
ABX464: A Potential Candidate With a Novel Mechanism of Action for the Treatment of Rheumatoid Arthritis
Summary
ABX464 met the primary endpoint revealing a favorable safety and tolerability profile in the Phase IIa clinical trial, displaying its potential and effectiveness for treating patients with moderate to severe RA and inadequate response to MTX and/or anti-TNFα therapeutics.
Article Type
Poster abstract
Title
Bimekizumab to Benefit Psoriatic Arthritis Patients According to the Phase III Clinical Trial Results
Summary
Bimekizumab met the primary and secondary endpoints with an acceptable safety profile in the Phase III clinical trial. It displayed its potential effectiveness for treating patients with active PsA and prior inadequate tumor necrosis factor inhibitor (TNFi) response.
Article Type
Title
Deucravacitinib: A Ray of Hope after a decade of wait! BMS plans to progress its potential game changer oral TYK2 inhibitor into late stage clinical development
Summary
BMS presented positive results of its 48-week Phase II study at EULAR 2022 indicating that deucravacitinib met both primary and secondary endpoints and was safe, well tolerated and effective for people with lupus. Study participants who received the oral drug saw greater improvements in several measures of disease activity, including overall activity and organ-specific activity, compared to the placebo group.
Article Type
Clinical Trials
Title
Dual inhibition of IL-17A & IL-17F with bimekizumab may be a promising treatment option for AS, suggests BE MOBILE 2 trial.
Summary
Bimekizumab met the primary and secondary endpoints with an acceptable safety profile in Phase III clinical trial, displaying its potential effectiveness for the treatment of patients with active AS and an inadequate response or intolerance to two nonsteroidal anti-inflammatory drugs and prior exposure to no more than one tumor necrosis factor (TNF) inhibitor.
Article Type
Clinical Trials
Title
Upadacitinib shows promising results for nr-axSpA treatment of patients with inadequate response to biologic disease-modifying antirheumatic drugs.
Summary
Upadacitinib met the primary and secondary endpoints with an acceptable safety profile in the Phase III clinical trial, displaying its potential effectiveness for the treatment of nr-axSpA in patients with inadequate response to biologic disease-modifying antirheumatic drugs.
Article Type
Clinical Trials
Case Studies
Partner Identification
Partners Identification for client's early-stage oncology-based clinical product for late-stage clinical development & commercialization.
Pipeline Assessment
Assessment of pipeline activities around the client's area of interest to support strategic decisions.
Epidemiology Assessment
In-depth assessment to understand the epidemiological scenario of Cutaneous Squamous Cell Carcinoma
Market Assessment
Evaluation of the oncological market potential of the asset gained through the acquisition and collaborations
Product Assessment
Performance evaluation of new assets based on the Lead and Lag KPI
Newsletter and Whitepapers
Gout Market is Anticipated to Expand Due to Active as well as Emerging Pipeline Therapies
Gout is a chronic disease caused by the deposition of monosodium urate (MSU) crystals in joints. It typically presents as an acute, self-limiting inflammatory monoarthritis that affects the joints of the lower limb. Various symptoms of Gout include intense joint pain, joint swelling, stiffness, tenderness, even to light touch, such as from a bedsheet, heat in the affected area, and joint redness.
Get Expert Consultation Now!
Our long standing experience and rich expertise in the rheumatology domain can be a perfect partner for your pressing business problems
Our in-depth knowledge of the rheumatology pipeline, granular understanding of market dynamics and acute perception of marketing nuances can help you create a highly successful plan for future performance.
Get in touch with us to discuss potential partnership and to know more about what we can offer you.
Delivering value through our expansive service offerings
Taking into account the highly dynamic landscape of rheumatology therapy area, it is of utmost importance to attain competitive edge early on in your business. With our repository of consulting solutions and market research offerings, we are well-positioned to advise you on how to navigate the barriers as well as leverage your strengths and opportunities.
We impart insights aimed at leveraging competitive advantage and formulating effective business growth strategies. Journey with us to realize opportunities as well as pitfalls, as we make it easier for you to capitalize your return on investment through our expert advice.
Involve us to help you collect insights on which asset could hold the most potential in the future.
Our 10-year forecast provides foresight for effective strategy-building for successful market entry
Our research expertise delivers real-time information that elevates your business decisions
We assist in navigating the tricky drug development terrain by providing intelligence assessments